Revolution Medicines Inc美股招股说明书(2026-04-15版)

10,563,381 Shares of Common Stock Common stock Revolution Medicines, Inc. is offering shares 10,563,381 of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.” The last reported sale price of our commonstock on the Nasdaq Global Select Market on April 14, 2026 was $147.01 per share. Concurrent convertible note offering Concurrently with this offering, we are offering, pursuant to a separate prospectus supplement, 0.50% convertible senior notes due 2033,which we refer to as the convertible notes, in an aggregate principal amount of $500,000,000. The completion of this offering is notcontingent on the completion of the concurrent convertible note offering, and the completion of the concurrent convertible note offering isnot contingent on the completion of this offering. Proceeds, before expenses, to us (1)See “Underwriting” for additional information regarding underwriting compensation. We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to1,584,506 additional shares of our common stock from us at the public offering price less the underwriting discounts and commissions. Investing in our securities involves significant risks. See “Risk factors” on page S-5 of this prospectus supplement and in thedocuments incorporated by reference in this prospectus supplement concerning factors you should consider before investingin our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock to purchasers on or about April 16, 2026.J.P.MorganTDCowenGuggenheimSecurities LifeSci Capital April 14, 2026 Table of contents Prospectus supplement About this prospectus supplementProspectus supplement summaryThe offeringRisk factorsSpecial note regarding forward-looking statements Market and industry data Capitalization Prospectus About This ProspectusWhere You Can Find More Information; Incorporation by ReferenceAbout the CompanyRisk FactorsUse of ProceedsDescription of Capital StockDescription of Debt SecuritiesDescription of Other SecuritiesGlobal SecuritiesPlan of DistributionLegal MattersExperts About this prospectus supplement This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of commonstock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by referenceinto this prospectus supplement and the accompanying prospectus. The second part is the accompanying prospectus dated March4,2024, included in our registration statement on Form S-3 (File No.333-277640), along with the documents incorporated by referencetherein, which provides more general information, some of which may not apply to this offering. Generally, when we refer to thisprospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained inthis prospectus supplement, on the one hand, and the information contained in the accompanying prospectus or in any documentincorporated by reference that was filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectussupplement, on the other hand, you should rely on the information contained in this prospectus supplement. If any statement in one ofthese documents is inconsistent with a statement in another document having a later date—for example, a document incorporated byreference in the accompanying prospectus—the statement in the document having the later date modifies or supersedes the earlierstatement. This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement that we filed with the SEC.Under this shelf registration process, we may offer from time to time various securities, of which this offering of shares of our commonstock is a part. Such registration statement also includes exhibits that provide more detail on the matters discussed in this prospectussupplement and the accompanying prospectus. You should read this prospectus supplement, the accompanying prospectus, including theinformation incorporated by reference herein and therein, the exhibits filed with the SEC, and any free writing prospectus that we haveauthorized for use in connection with this offering, in their entirety before making an investment decision. We have not, and the underwriters have not, authorized anyone to provide you with information, or to make any representation, differentfrom that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along with theinformation contai